Drug intelligence / Profile preview

INI-4001 + nivolumab

Development stage: Unknown
Lead developer: Inimmune
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Unknown For INI-4001 (likely Intravenous Or Subcutaneous As Nanoparticle Injection)

Overview

A combination regimen consisting of **INI-4001**, a novel small molecule **TLR7/8 (Toll-like receptor 7/8) agonist** in a nanoparticle delivery system, and **nivolumab**, a monoclonal antibody checkpoint inhibitor targeting PD-1 (Programmed cell death protein 1). INI-4001 is being developed for the induction of anti-tumor immune responses and for sensitization to immune checkpoint inhibitor therapy in patients with advanced solid tumors. Nivolumab (Opdivo) is an approved PD-1 inhibitor used in various cancers. In this experimental combination, INI-4001 activates innate immunity (notably by increasing IFNα and activating antigen-presenting cells), and when used with nivolumab, aims to enhance T cell activation and anti-tumor immune response. This combination is currently in Phase 1 clinical development for advanced solid tumors[1][2][3][5].

Other names: nivolumab

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on INI-4001 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INI-4001 + nivolumab.

Explore the full profile